

Learner Notification

MED Learning Group

Integrating Antibody Therapeutics in the Management of NHL: Best Practices for the Multidisciplinary Oncology Care Team

December 20, 2023 – December 20, 2024

Online

Acknowledgement of Financial Commercial Support

ADC Therapeutics America, Inc., Genentech

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Summarize the role of antibody therapeutics, including novel bispecific antibodies and combinations for the management of NHL.
2. Evaluate current clinical trial data on antibody therapeutics, including bispecific antibody therapies in B-cell NHL.
3. Analyze adverse event management best practices for the multidisciplinary oncology care team using antibody therapeutics, including bispecific antibodies, for the management of NHL.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Emmanuella	Foucault	NA
Matthew	Frese	NA
Christina	Gallo	NA
Sharine	Griggs	NA
Sylvia	Hanna	NA
Reem	Karmali	BeiGene, AstraZeneca, Morphosys/Incyte, Bristol Myers Squibb, Kite, Genentech, Miltenyi Biotec, Lilly, Calithera, Janssen: Consultant; BeiGene, AstraZeneca, Morphosys/Incyte: Speakers Bureau
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com